EvaluatePharma’s 10 best-selling drugs in 2026 and their expected global sales:
- Keytruda (Merck) — $24.9 billion
- Opdivo (Bristol Myers Squibb) — $12.7 billion
- Eliquis (Bristol Myers Squibb) — $12.6 billion
- Biktarvy (Gilead) — $11.7 billion
- Imbruvica (AbbVie + Johnson & Johnson) — $10.7 billion
- Ibrance (Pfizer) — $9.7 billion
- Tagrisso (AstraZeneca) — $9.5 billion
- Dupixent (Sanofi) — $9.4 billion
- Trikafta (Vertex Pharmaceuticals) —$8.7 billion
- Ozempic (Novo Nordisk) — $8.3 billion
More articles on pharmacy:
Walgreens CEO steps down
AstraZeneca, Daiichi Sankyo partner in $6B cancer drug deal
Trump signs 4 executive orders targeting drug prices: 6 things to know
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
